Beta receptor blocker therapy for the elderly in the COVID-19 era

作     者：Elpidio Santillo Monica Migale 

作者机构：Geriatric Rehabilitative DepartmentIRCCS-INRCAFermo 63900Italy 

出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)

年 卷 期：2022年第10卷第23期

页      面：8088-8096页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：Adrenergic beta-antagonist COVID-19 Aged SARS-CoV-2 Cardiovascular diseases 

摘      要：When the coronavirus disease 2019(COVID-19)pandemic spread globally from the Hubei region of China in December 2019,the impact on elderly people was particularly *** mortality associated with severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection was highest in older individuals,in whom frailty and comorbidities increased susceptibility to severe forms of ***,in older patients,the course of COVID-19 was often characterized by significant cardiovascular complications,such as heart failure decompensation,arrhythmias,pericarditis,and *** that the elderly have adequate therapeutic coverage against known cardiovascular diseases and risk factors is particularly important in the COVID-19 *** blockers are widely used for the treatment and prevention of cardiovascular *** clinical benefits of beta blockers have been confirmed in elderly patients,and in addition to their negative chronotropic effect,sympathetic inhibition and anti-inflammatory activity are theoretically of great benefit for the treatment of COVID-19 *** blockers have not been clearly shown to prevent SARS-CoV-2 infection,but there is evidence from published studies including elderly patients that beta blockers are associated with a more favorable clinical course of COVID-19 and reduced *** this minireview,we summarize the most important evidence available in the literature on the usefulness of beta blocker therapy for older patients in the context of the COVID-19 pandemic.